September 17, 2013
Mark Noble, Ph.D.
A team from the University of Rochester Medical Center has shown scientifically what many women report anecdotally: that the breast cancer drug tamoxifen is toxic to cells of the brain and central nervous system, producing mental fogginess similar to
However, in the Journal of Neuroscience, researchers also report they've discovered an existing drug compound that appears to counteract or rescue brain cells from the adverse effects of the breast cancer drug.
Corresponding author Mark Noble, Ph.D., professor of Biomedical Genetics and director of the UR Stem Cell and Regenerative Medicine Institute, said it's exciting to potentially be able to prevent a toxic reaction to one of the oldest and most widely used breast cancer medications on the market. Although tamoxifen is more easily tolerated compared to most cancer treatments, it nonetheless produces troubling side effects in a subset of the large number of people who take it.
June 27, 2013
An estimated 14,380 Americans this year will get the news. They have head and neck cancer. Most will receive carefully calibrated doses of radiation therapy each day over several weeks to kill cancer cells and shrink the tumor. At some point, more than 90 percent will notice an unpleasant parched sensation in their mouths. It is a side effect of the radiation treatment called xerostomia, or dry mouth. For most, the persistent dryness will become a permanent part of their lives, causing difficulty with eating and speaking, oral infections, dental caries, tissue inflammation, and decreased quality of life.
In the June issue of the journal Molecular Therapy, a team of NIDCR-supported scientists report initial success in reducing apoptosis in the submandibular salivary gland in mice. They do so using short interfering RNAs (siRNAs), which are small RNA molecules that can be introduced into a cell to block temporarily the expression of a protein.
May 1, 2013
Mark Noble, Ph.D. and doctoral student Hsing-Yu Chen studied the molecular mechanism that allows basal-like breast cancer cells to escape the secondary effects of tamoxifen, and discovered that two proteins are critical in this escape.
The research, published in the journal EMBO Molecular Medicine, shows how to exploit tamoxifen's secondary activities so that it might work on more aggressive breast cancer—a promising development for women with basal-like breast cancer, sometimes known as triple-negative disease.
April 23, 2013
Tamoxifen is a time-honored breast cancer drug used to treat millions of women with early-stage and less-aggressive disease, and now a University of Rochester Medical Center team has shown how to exploit tamoxifen's secondary activities so that it might work on more aggressive breast cancer.
The research, published in the journal EMBO Molecular Medicine, is a promising development for women with basal-like breast cancer, sometimes known as triple-negative disease. Led by doctoral student Hsing-Yu Chen and Mark Noble, Ph.D., professor of Biomedical Genetics at URMC, the team studied the molecular mechanism that allows basal-like breast cancer cells to escape the secondary effects of tamoxifen, and discovered that two proteins are critical in this escape.
For more information and details on how to apply please visit the Office for Graduate Education and Postdoctoral Affairs.